FDA tool ranks imports by risk

While acknowledging that the global supply chain makes it impossible for FDA to "interdict everything harmful at our borders," FDA Commissioner Margaret Hamburg last week unveiled a system that will improve interdiction efforts. The system prioritizes imports for inspection using risk-based tactics along the lines of those the FDA advocates for drugmakers' use in their manufacturing operations. 

PREDICT--the Predictive Risk-Based Evaluation for Dynamic Import Compliance Targeting--stores information from previous examinations of shippers and producers, environmental data, and other information affecting the current shipment and then calculates a risk score for inspector triage. The system "will allow us to monitor products at the port of entry more reliably and to target shipments for inspection that pose the greatest risk," Hamburg says.

PREDICT is being rolled out in New York now, following testing in Los Angeles.

"Every day, FDA rejects imports at the border for a range of problems including illegal drug residues, bacterial contamination, unapproved food additives, pesticides, heavy metals, and just plain filth," Hamburg says. Just 500 inspectors will oversee some 20 million shipments of FDA-regulated imports this year. They examine less than 1 percent before the products enter the U.S.

- read Hamburg's remarks

Suggested Articles

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.